PARP inhibitors: current status and implications for anticancer therapeutics

被引：5

作者：

Usmani, Hadi ^{[1
]}

Hussain, Syed Ather ^{[1
]}

Sheikh, Asfandyar ^{[1
,2
]}

机构：

[1] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan

[2] Pakistan Res Evolut Sci Soc, Karachi 74200, Pakistan

来源：

INFECTIOUS AGENTS AND CANCER | 2013年 / 8卷

关键词：

POLY(ADP-RIBOSE) POLYMERASE; TUMORS;

D O I：

10.1186/1750-9378-8-46

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly(ADP-ribose) polymerases (PARPs) comprise of a large family of 17 proteins encoded by various genes which participate in genome maintenance, apoptosis, inflammatory responses and the regulation of gene expression programs. PARP inhibitors, as therapeutic agents, come into play acting on both PARP 1 and PARP 2. These drugs seem to target tumor cells in a moment of vulnerability when they are undergoing DNA repair. In the past few years this class of anti-cancer drug has been discovered to show a promising niche in the clinic.

引用

页数：3

共 50 条

[1] PARP inhibitors: current status and implications for anticancer therapeutics
Hadi Usmani
Syed Ather Hussain
Asfandyar Sheikh
[J]. Infectious Agents and Cancer, 8
[2] Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives
Wang, Hui
Yang, Qingzhu
Dou, Q. Ping
Yang, Huanjie
[J]. CURRENT PROTEIN & PEPTIDE SCIENCE, 2018, 19 (04) : 358 - 367
[3] The current status of PARP inhibitors in ovarian cancer
McLachlan, Jennifer
George, Angela
Banerjee, Susana
[J]. TUMORI JOURNAL, 2016, 102 (05): : 433 - 440
[4] Akt inhibitors: mechanism of action and implications for anticancer therapeutics
Jaikrit Bhutani
Asfandyar Sheikh
Asfandyar Khan Niazi
[J]. Infectious Agents and Cancer, 8
[5] Akt inhibitors: mechanism of action and implications for anticancer therapeutics
Bhutani, Jaikrit
Sheikh, Asfandyar
Niazi, Asfandyar Khan
[J]. INFECTIOUS AGENTS AND CANCER, 2013, 8
[6] PARP Inhibitors in Endometrial Cancer: Status and Perspectives Current
Musacchio, Lucia
Caruso, Giuseppe
Pisano, Carmela
Cecere, Sabrina Chiara
Di Napoli, Marilena
Attademo, Laura
Tambaro, Rosa
Russo, Daniela
Califano, Daniela
Palaia, Innocenza
Muzii, Ludovico
Panici, Pierluigi Benedetti
Pignata, Sandro
[J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6123 - 6135
[7] PARP inhibitors for anticancer therapy
Curtin, Nicola
[J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2014, 42 : 82 - 88
[8] Synthetic lethality in cancer treatment: Current status of PARP inhibitors
Calvert, A. H.
[J]. ANNALS OF ONCOLOGY, 2011, 22 : 13 - 13
[9] PARP inhibitors in ovarian cancer: Current status and future promise
Liu, Joyce F.
Konstantinopoulos, Panagiotis A.
Matulonis, Ursula A.
[J]. GYNECOLOGIC ONCOLOGY, 2014, 133 (02) : 362 - 369
[10] PARP Inhibitors in Breast Cancer: Current Status and Future Directions
Isakoff, Steven J.
[J]. ONCOLOGIST, 2017, 22 : S3 - S3

← 1 2 3 4 5 →